Astria Therapeutics is a biopharmaceutical company which focuses on therapies to treat allergic and immunological diseases. The company's program include STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Astria Therapeutics, formerly known as Catabasis Pharmaceuticals Inc., is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-94.26M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -56.39% |
| Return on Assets (Trailing 12 Months) | -36.08% |
| Current Ratio (Most Recent Fiscal Quarter) | 14.89 |
| Quick Ratio (Most Recent Fiscal Quarter) | 14.89 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.93 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.57 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.68 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 56.44M |
| Free Float | 53.90M |
| Market Capitalization | $367.39M |
| Average Volume (Last 20 Days) | 0.27M |
| Beta (Past 60 Months) | 0.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 98.98% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |